196 related articles for article (PubMed ID: 18642288)
1. Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes.
Buch SC; Nazar-Stewart V; Weissfeld JL; Romkes M
Head Neck; 2008 Sep; 30(9):1139-47. PubMed ID: 18642288
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma.
Morita S; Yano M; Tsujinaka T; Akiyama Y; Taniguchi M; Kaneko K; Miki H; Fujii T; Yoshino K; Kusuoka H; Monden M
Int J Cancer; 1999 Mar; 80(5):685-8. PubMed ID: 10048967
[TBL] [Abstract][Full Text] [Related]
3. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case-control study in Rio de Janeiro.
Marques CF; Koifman S; Koifman RJ; Boffetta P; Brennan P; Hatagima A
Oral Oncol; 2006 Jul; 42(6):632-7. PubMed ID: 16488179
[TBL] [Abstract][Full Text] [Related]
5. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population.
Boccia S; Sayed-Tabatabaei FA; Persiani R; Gianfagna F; Rausei S; Arzani D; La Greca A; D'Ugo D; La Torre G; van Duijn CM; Ricciardi G
BMC Cancer; 2007 Nov; 7():206. PubMed ID: 17996038
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer.
Hahn M; Hagedorn G; Kuhlisch E; Schackert HK; Eckelt U
Oral Oncol; 2002 Jul; 38(5):486-90. PubMed ID: 12110344
[TBL] [Abstract][Full Text] [Related]
8. CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer.
Boccia S; Cadoni G; Sayed-Tabatabaei FA; Volante M; Arzani D; De Lauretis A; Cattel C; Almadori G; van Duijn CM; Paludetti G; Ricciardi G
J Cancer Res Clin Oncol; 2008 Jan; 134(1):93-100. PubMed ID: 17611777
[TBL] [Abstract][Full Text] [Related]
9. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.
Troy JD; Weissfeld JL; Diergaarde B; Youk AO; Buch SC; Romkes M; Grandis JR
Cancer Epidemiol; 2013 Aug; 37(4):505-11. PubMed ID: 23523331
[TBL] [Abstract][Full Text] [Related]
11. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people.
Katoh T; Kaneko S; Boissy R; Watson M; Ikemura K; Bell DA
Carcinogenesis; 1998 Oct; 19(10):1803-7. PubMed ID: 9806162
[TBL] [Abstract][Full Text] [Related]
12. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas.
Matthias C; Bockmühl U; Jahnke V; Harries LW; Wolf CR; Jones PW; Alldersea J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Feb; 8(1):1-6. PubMed ID: 9511175
[TBL] [Abstract][Full Text] [Related]
13. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of phase I and phase II metabolic enzymes as modulators of lung cancer susceptibility.
Mota P; Silva HC; Soares MJ; Pego A; Loureiro M; Cordeiro CR; Regateiro FJ
J Cancer Res Clin Oncol; 2015 May; 141(5):851-60. PubMed ID: 25388590
[TBL] [Abstract][Full Text] [Related]
15. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer.
Olshan AF; Weissler MC; Watson MA; Bell DA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):185-91. PubMed ID: 10698480
[TBL] [Abstract][Full Text] [Related]
16. CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung.
Larsen JE; Colosimo ML; Yang IA; Bowman R; Zimmerman PV; Fong KM
Carcinogenesis; 2006 Mar; 27(3):525-32. PubMed ID: 16195240
[TBL] [Abstract][Full Text] [Related]
17. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers.
Matthias C; Bockmühl U; Jahnke V; Jones PW; Hayes JD; Alldersea J; Gilford J; Bailey L; Bath J; Worrall SF; Hand P; Fryer AA; Strange RC
Pharmacogenetics; 1998 Apr; 8(2):91-100. PubMed ID: 10022746
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
[TBL] [Abstract][Full Text] [Related]
20. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Sun F; Chen Y; Xiang Y; Zhan S
Int J Tuberc Lung Dis; 2008 Sep; 12(9):994-1002. PubMed ID: 18713495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
